Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.26 USD
Change Today +0.12 / 2.90%
Volume 4.8K
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

lombard medical inc (EVAR) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/18/14 - $7.78
52 Week Low
03/30/15 - $3.55
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for LOMBARD MEDICAL INC (EVAR)

Related News

No related news articles were found.

lombard medical inc (EVAR) Related Businessweek News

No Related Businessweek News Found

lombard medical inc (EVAR) Details

Lombard Medical, Inc., a medical technology company, develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms in the United States, the United Kingdom, Germany, Japan, and internationally. The company’s principal product is Aorfix, which is an endovascular stent-graft for the treatment of an abdominal aortic aneurysm with angulation at the neck of the aneurysm of up to 90 degrees. It is also developing stent-graft system to treat thoracic aortic aneurysms. Lombard Medical, Inc. sells its products directly through its direct sales force and third-party distributors. The company was founded in 2000 and is headquartered in Irvine, California.

192 Employees
Last Reported Date: 04/30/15
Founded in 2000

lombard medical inc (EVAR) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $592.9K
Chief Financial Officer
Total Annual Compensation: $19.4K
President of North America
Total Annual Compensation: $313.1K
Vice President of Global Clinical & Regulator...
Total Annual Compensation: $265.8K
Vice President of Global Innovation and Devel...
Total Annual Compensation: $85.9K
Compensation as of Fiscal Year 2014.

lombard medical inc (EVAR) Key Developments

Lombard Medical, Inc. Announces Completion of First Clinical Cases Using its New Aorfix Plus Endovascular Stent Graft

Lombard Medical, Inc. announced that the first clinical cases using its new Aorfix Plus endovascular stent graft have been successfully completed. The new addition to the Aorfix endovascular stent graft portfolio was recently approved by the FDA, increasing the upper range of treatable aortic neck diameters up to 33mm. Up to 10% more patients with an abdominal aortic aneurysms have the potential to be treated with the Aorfix device as a result of the expanded size range. Aorfix is the only endovascular stent graft with global regulatory approvals for the treatment of patients with aortic neck angulations up to 90 degrees, often a feature of complex abdominal aortic aneurysms anatomies. Aorfix is an endovascular stent graft system for treating infra-renal aortic and aorto-iliac aneurysms, also known as abdominal aortic aneurysms (AAAs). When placed within the aneurysm, Aorfix creates an internal bypass of the aneurysm to reduce the risk of rupture. Aorfix is the first and only endovascular stent graft with global approvals for the treatment of patients with aortic neck angulations up to 90 degrees. Aorfix features an exclusive helical and circular design that allows it to conform to the natural contours of human anatomy, including aortic necks with high angulations and iliac arteries with extreme bends. Aorfix has been evaluated in three studies and used in more than 4,000 procedures worldwide. Aorfix received FDA approval in 2013, and is commercially available in U.S., U.K., Germany, Spain, Italy, Austria, Switzerland, the Czech Republic, Russia, Greece, Canada, Mexico, Brazil, Japan, Hong Kong, Poland, New Zealand, Argentina, Sweden, Colombia, Ireland, Chile, Peru, and Uruguay.

Lombard Medical, Inc. Enters Group Purchasing Agreement with Novation to Offer Aorfix Endovascular Stent Graft

Lombard Medical, Inc. signed a three-year group purchasing agreement with Novation to offer its Aorfix's Endovascular Stent Graft to the more than 100,000 members and affiliates that Novation serves. Novation selected Aorfix as part of its Innovative Technology program, which is designed to ensure that members have access to innovative health care technology. As part of its rigorous review process, Novation evaluated two-year outcomes data from the Aorfix PYTHAGORAS pivotal trial, to evaluate EVAR treatment outcomes in patients with complex, difficult-to-treat anatomies. The data showed that Aorfix delivered comparable results to other devices used to treat patients with typical, less challenging anatomies.

Lombard Medical, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 04:30 PM

Lombard Medical, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 04:30 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Simon Hubbert, Chief Executive Officer and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EVAR:US $4.26 USD +0.12

EVAR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AtriCure Inc $23.76 USD -0.26
CryoLife Inc $11.28 USD -0.03
LeMaitre Vascular Inc $11.30 USD -0.78
TriVascular Technologies Inc $5.42 USD -0.03
Vascular Solutions Inc $34.32 USD -0.47
View Industry Companies

Industry Analysis


Industry Average

Valuation EVAR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.7x
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LOMBARD MEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at